ES2532497T3 - Uso de acetil-L-carnitina para la preparación de un medicamento para el tratamiento del dolor neuropático en pacientes diabéticos - Google Patents

Uso de acetil-L-carnitina para la preparación de un medicamento para el tratamiento del dolor neuropático en pacientes diabéticos Download PDF

Info

Publication number
ES2532497T3
ES2532497T3 ES05730316.6T ES05730316T ES2532497T3 ES 2532497 T3 ES2532497 T3 ES 2532497T3 ES 05730316 T ES05730316 T ES 05730316T ES 2532497 T3 ES2532497 T3 ES 2532497T3
Authority
ES
Spain
Prior art keywords
patients
carnitine
acetyl
treatment
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05730316.6T
Other languages
English (en)
Spanish (es)
Inventor
Menotti Calvani
Antonino Amato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2532497T3 publication Critical patent/ES2532497T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
ES05730316.6T 2004-07-01 2005-04-05 Uso de acetil-L-carnitina para la preparación de un medicamento para el tratamiento del dolor neuropático en pacientes diabéticos Expired - Lifetime ES2532497T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000327A ITRM20040327A1 (it) 2004-07-01 2004-07-01 Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
ITRM20040327 2004-07-01
PCT/EP2005/003557 WO2006002698A1 (en) 2004-07-01 2005-04-05 Use of acetyl l-carnitine for the preparation of a medicine for the treatment of neuropathic pain in diabetic patients

Publications (1)

Publication Number Publication Date
ES2532497T3 true ES2532497T3 (es) 2015-03-27

Family

ID=34965656

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05730316.6T Expired - Lifetime ES2532497T3 (es) 2004-07-01 2005-04-05 Uso de acetil-L-carnitina para la preparación de un medicamento para el tratamiento del dolor neuropático en pacientes diabéticos

Country Status (14)

Country Link
US (2) US20060004095A1 (https=)
EP (1) EP1761257B1 (https=)
JP (1) JP5519907B2 (https=)
KR (1) KR101176347B1 (https=)
CA (1) CA2570268C (https=)
CY (1) CY1116171T1 (https=)
DK (1) DK1761257T3 (https=)
ES (1) ES2532497T3 (https=)
IT (1) ITRM20040327A1 (https=)
MX (1) MXPA06014907A (https=)
PL (1) PL1761257T3 (https=)
PT (1) PT1761257E (https=)
SI (1) SI1761257T1 (https=)
WO (1) WO2006002698A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03006266A (es) * 2000-12-15 2004-06-25 Sigma Tau Ind Farmaceuti Uso de l-carnitina como agente estabilizador de proteinas.
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1133010B (it) * 1980-05-15 1986-07-09 Sigma Tau Ind Farmaceuti Metodo terapuetico per il trattamento del diabete mellito a insorgenza giovanile e composizione farmaceutica per tale metodo
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
IT1224842B (it) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
US5827886A (en) * 1997-05-07 1998-10-27 Thione International, Inc. Composition for relief of arthritis-induced symptoms
IT1294227B1 (it) * 1997-08-01 1999-03-24 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione
IT1306178B1 (it) * 1999-07-27 2001-05-30 Sigma Tau Ind Farmaceuti Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento utile nel trattamento del paziente affetto da
ITRM20010294A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re

Also Published As

Publication number Publication date
EP1761257A1 (en) 2007-03-14
JP2008505134A (ja) 2008-02-21
CY1116171T1 (el) 2017-02-08
DK1761257T3 (en) 2015-03-23
MXPA06014907A (es) 2007-03-21
PT1761257E (pt) 2015-04-14
KR101176347B1 (ko) 2012-08-24
PL1761257T3 (pl) 2015-06-30
EP1761257B1 (en) 2014-12-31
SI1761257T1 (sl) 2015-04-30
JP5519907B2 (ja) 2014-06-11
WO2006002698A1 (en) 2006-01-12
KR20070042963A (ko) 2007-04-24
US20060004095A1 (en) 2006-01-05
ITRM20040327A1 (it) 2004-10-01
CA2570268A1 (en) 2006-01-12
CA2570268C (en) 2013-10-15
US20070213408A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
Bolton Neuromuscular manifestations of critical illness
US6335361B1 (en) Method of treating benign forgetfulness
Kongkam et al. Propofol infusion versus intermittent meperidine and midazolam injection for conscious sedation in ERCP
KR960705556A (ko) 비타민 k를 사용하여 피부의 혈관 질환을 처치하는 방법 및 조성물(composition and method for treating blood vessel disorders of the skin using vitamin k)
ES2797688T3 (es) Arginina silicato inositol para mejorar la función cognitiva
ES2925775T3 (es) Esteres de ácido azelaico en el tratamiento de la resistencia a la insulina
WO2018097734A1 (en) Prevention and/or treatment of hyperlactataemia
JP4276779B2 (ja) 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用
ES2532497T3 (es) Uso de acetil-L-carnitina para la preparación de un medicamento para el tratamiento del dolor neuropático en pacientes diabéticos
US20080161604A1 (en) Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy
ES2268053T3 (es) Uso de acetil l-carnitina en asociacion con biotina para el tratamiento de pacientes con diabetes mellitus de tipo 2 resistente a insulina.
US8952059B2 (en) Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes
ES2425045T3 (es) Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa
ES2608398T3 (es) Utilización de hierro para el tratamiento del trastorno del déficit de atención/hiperactividad en niños
DE04291738T1 (de) Verwendung von Citrullin zur Herstellung eines Arzneimittels zur Behandlung von intestinaler Insuffizienz
JP5685362B2 (ja) 有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン
Singh et al. Pregabalin versus gabapentin in the management of painful Diabetic neuropathy
Sharda A study on the role of omega fatty acids as an adjuvant therapy in treatment of amblyopia
Roshanzamiri et al. Serotonin Syndrome due to Concomitant use of Linezolid and Methadone
EA052270B1 (ru) Способ профилактики нарушений когнитивной функции
PT2229943E (pt) Composto para ser utilizado no tratamento das neuropatias periféricas.
PT1399143E (pt) Utilização da acetil-l-carnitina na preparação de um medicamento para tratar a anedonia
Nylen The role of acetone in the anticonvulsant actions of the ketogenic diet in rats
McCarron Annotated Abstracts
PT1773314E (pt) Uso de l-carnitina para o tratamento de doenças cardiovasculares